Nuwiq (Human coagulation factor VIII [rDNA], simoctocog alfa) for Hemophilia | MyHemophiliaTeam

Connect with others who understand.

sign up log in
About MyHemophiliaTeam
Powered By

Nuwiq is approved by the Food and Drug Administration (FDA) to treat and prevent bleeding episodes in children and adults with hemophilia A (congenital factor VIII deficiency). The technical name of Nuwiq is Human coagulation factor VIII (rDNA), simoctocog alfa.

Nuwiq is a clotting factor. Clotting factors work by supplying proteins missing in people with bleeding disorders.

How do I take it?
Prescribing information states that Nuwiq is given as an intravenous injection.

Nuwiq comes as a powder that must be reconstituted before injection.

Side effects
The FDA-approved label for Nuwiq does not list common side effects. Less commonly, Nuwiq may cause headache, dry mouth, vertigo, pins-and-needles sensations, back pain, and pain at injection site.

Rare but serious side effects listed for Nuwiq include life-threatening hypersensitivity reactions, complications involving the catheter of the central venous access device (CVAD), and the development of inhibitors.

For more details about this treatment, visit:

Treatment of Hemophilia – Hemophilia Federation of America

Continue with Facebook
Continue with Google
Your privacy is our priority. By continuing, you accept our Terms of Use and Privacy Policy.
Already a Member? Log in